NCT01781117View on ClinicalTrials.gov

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

NACompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
Benign Prostatic Hypertrophy With Outflow ObstructionOveractive Detrusor
Interventions
PROCEDURE

Holmium Laser Enucleation of the Prostate (HoLEP)

Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.

DEVICE

Holmium laser enucleation system and morcellator

Holmium laser enucleation and morcellation

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

lead

KYU-SUNG LEE

OTHER

NCT01781117 - Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter